RDG.WAR Readgene

Healthcare Biotechnology Warsaw Stock Exchange
4.99 PLN
Close of Oct 29, 2026
4.60 6.18
Market cap
PLN 58.8M
P/E
49.9x
P/B
24.18x
ROE
37.8%
Dividend yield
-
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RDG.WAR undervalued?

Graham number

The Graham number of Readgene cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Readgene fundamental analysis

7 of 22 checks passed

ROE 2/2

High return on equity (37.8%), above 20%.

ROA 1/1

Return on assets (7.0%) is above the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (108.7%) is above the 5-year average (-15.6% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (108.7%) is above the industry median (2.6%).

Revenue Growth 2/2

Revenue grew 29.2% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 67,923.8x against interest expense, well covered.

PE vs Market 0/1

PE (49.9x) is above the market median (11.6x).

PE vs Industry 0/1

PE (49.9x) is above the industry median (18.6x).

PBV 0/1

Price to book (24.2x) is above the industry median (3.6x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 1,206.4, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Readgene stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Readgene

Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries. In addition, the comp…

Full company profile